In a study that investigated the effects of combination trastuzumab HER2-targeted therapy with adjuvant chemotherapy, 1 year of trastuzumab treatment significantly increased disease-free survival in breast cancer patients following the completion of primary therapy compared with no treatment groups.90 Along with this result, trastuzumab therapy allowed for extended immune recruitment at the tumor site compared to control groups, which opened the door for subsequent Her2-NIR-PIT that would enhance the antitumor immunity effect. The gene discussed is ERBB2; the disease is neoplasm.